Lexeo Therapeutics, Inc. financial data

Symbol
LXEO on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 487% % -38%
Debt-to-equity 28% % 41%
Return On Equity -90% % -57%
Return On Assets -71% % -47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 72,987,327 shares 121%
Common Stock, Shares, Outstanding 54,934,275 shares 66%
Entity Public Float $527,900,000 USD
Common Stock, Value, Issued $5,000 USD 67%
Weighted Average Number of Shares Outstanding, Basic 60,980,867 shares 84%
Weighted Average Number of Shares Outstanding, Diluted 60,980,867 shares 84%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $65,953,000 USD 3.2%
General and Administrative Expense $47,570,000 USD 62%
Operating Income (Loss) $113,523,000 USD -22%
Nonoperating Income (Expense) $8,557,000 USD 27%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $104,966,000 USD -21%
Net Income (Loss) Attributable to Parent $104,933,000 USD -21%
Earnings Per Share, Basic -2 USD/shares -115%
Earnings Per Share, Diluted -2 USD/shares -115%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $40,996,000 USD -74%
Cash, Cash Equivalents, and Short-term Investments $106,900,000 USD
Assets, Current $127,793,000 USD -20%
Property, Plant and Equipment, Net $1,230,000 USD 4.2%
Operating Lease, Right-of-Use Asset $6,963,000 USD -17%
Assets $143,844,000 USD -17%
Accounts Payable, Current $4,656,000 USD -45%
Liabilities, Current $17,271,000 USD -36%
Operating Lease, Liability, Noncurrent $5,288,000 USD -22%
Liabilities $23,013,000 USD -33%
Accumulated Other Comprehensive Income (Loss), Net of Tax $89,000 USD
Retained Earnings (Accumulated Deficit) $359,215,000 USD -41%
Stockholders' Equity Attributable to Parent $120,831,000 USD -13%
Liabilities and Equity $143,844,000 USD -17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $21,716,000 USD -46%
Net Cash Provided by (Used in) Financing Activities $88,654,000 USD
Net Cash Provided by (Used in) Investing Activities $15,600,000 USD
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 54,935,477 shares 66%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $6,105,000 USD -108%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $44,244,000 USD -72%
Deferred Tax Assets, Valuation Allowance $95,426,000 USD 54%
Deferred Tax Assets, Gross $98,404,000 USD 51%
Operating Lease, Liability $7,435,000 USD -16%
Payments to Acquire Property, Plant, and Equipment $185,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $104,877,000 USD 32%
Lessee, Operating Lease, Liability, to be Paid $8,702,000 USD -20%
Property, Plant and Equipment, Gross $1,898,000 USD 6%
Operating Lease, Liability, Current $2,147,000 USD 1.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,261,000 USD 2.5%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,206,000 USD 2.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,267,000 USD -35%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,318,000 USD 2.5%
Deferred Tax Assets, Operating Loss Carryforwards $33,295,000 USD 52%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,372,000 USD -41%
Operating Lease, Payments $2,139,000 USD 2%
Deferred Tax Assets, Net of Valuation Allowance $2,978,000 USD -12%
Share-based Payment Arrangement, Expense $12,926,000 USD 32%
Interest Expense $174,000 USD -34%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%